Home Cart Sign in  
Chemical Structure| 63610-08-2 Chemical Structure| 63610-08-2

Structure of Indobufen
CAS No.: 63610-08-2

Chemical Structure| 63610-08-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Indobufen is a platelet aggregation inhibitor and a reversible cyclooxygenase inhibitor. It has been used in studying the supportive care and prevention of Atrial Fibrillation.

Synonyms: Ibustrin; K 3920

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Indobufen

CAS No. :63610-08-2
Formula : C18H17NO3
M.W : 295.33
SMILES Code : O=C(O)C(CC)C1=CC=C(N(CC2=C3C=CC=C2)C3=O)C=C1
Synonyms :
Ibustrin; K 3920
MDL No. :MFCD00572250
InChI Key :AYDXAULLCROVIT-UHFFFAOYSA-N
Pubchem ID :107641

Safety of Indobufen

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Rabbit platelets 0.1, 0.2, 0.4, 0.6, 0.8 mmol/L 5 minutes Evaluate the inhibitory effect of Indobufen on ADP-induced platelet aggregation. Results showed that Indobufen significantly inhibited platelet aggregation, and the effect was stronger than Ticlopidine. Pharmaceutics. 2023 Aug 14;15(8):2135
Rabbit platelets 2, 4, 6, 8 μmol/L 5 minutes Evaluate the inhibitory effect of Indobufen on AA-induced platelet aggregation. Results showed that Indobufen significantly inhibited platelet aggregation, and the effect was stronger than aspirin. Pharmaceutics. 2023 Aug 14;15(8):2135
Rabbit plasma 20 mg/kg 5 days Evaluate the effect of Indobufen on APTT, PT, and TT in rabbit plasma, results showed that Indobufen significantly prolonged APTT, PT, and TT. Molecules. 2018 Jun 15;23(6):1452
platelets 0–128 mg/L 10 minutes To evaluate the inhibitory effect of S- and R-indobufen on platelet aggregation. The S-form was more potent, whereas the R-form showed less inter-individual variation. Transl Clin Pharmacol. 2018 Dec;26(4):160-165

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SD rats Gastric ulcer model Oral gavage 20, 30, 40 mg/kg Once daily for 8 consecutive days Evaluate the effect of Indobufen on gastric ulcers. Results showed that the incidence of gastric ulcers in the low and medium dose Indobufen groups was significantly lower than that in the aspirin group, while the high dose group was higher than the aspirin group. Pharmaceutics. 2023 Aug 14;15(8):2135
Mice Bleeding time and clotting time model Intragastric administration 160, 80, 40 mg/kg Once daily for 5 days Evaluate the effect of Indobufen on bleeding time and clotting time in mice, results showed that Indobufen significantly prolonged bleeding time and clotting time. Molecules. 2018 Jun 15;23(6):1452
Wistar rats Adenine-induced chronic kidney disease model Oral 20 mg/kg/day Once daily for 4 weeks and 8 weeks To compare the effects of indobufen with warfarin in a rat model of adenine-induced CKD. Results showed that the degree of kidney fibrosis in the indobufen group was significantly lower than that in the DMSO and warfarin groups. Med Sci Monit. 2019 May 14;25:3566-3572

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01232023 Healthy PHASE1 UNKNOWN - Pusan National University Yang... More >>san Hospital, Pusan, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.39mL

0.68mL

0.34mL

16.93mL

3.39mL

1.69mL

33.86mL

6.77mL

3.39mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories